European Patent Application EP4358984A1, published on March 11, 2026, describes a novel combination therapy for treating prostate cancer. The patented treatment involves the synergistic use of an oncolytic virus, an anti-PD-1 inhibitor, and an activator of the innate immune system. This application is filed by Folkan, Gro and lists ROLF, Seljelid as the inventor.

This document represents a patent publication, not a regulatory rule or enforcement action. It outlines a potential therapeutic approach and does not impose immediate compliance obligations on regulated entities. However, companies involved in pharmaceutical development, particularly in oncology and immunotherapy, should be aware of this patent as it may impact future research, development, and commercialization strategies in this therapeutic area.